Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Infantile hepatic hemangioendothelioma (IHHE) is an infantile hemangioma involving the
liver.Since 2008, propranolol has been used for the treatment of hemangioma, and some
researchers have also started to report the use of propranolol for the treatment of infantile
hepatic hemangioma in children. Sirolimus can be used in patients with vascular malformations
such as hemangiomas. IHHE is also an infantile hemangioma involving the liver,thus sirolimus
may paly the role in treatment of IHHE.The clinical trial explores the efficacy of sequential
treatment of sirolimus to refractory IHHE patients resistant with propranolol, to improve the
therapeutic effect, reduce the side effects of traditional treatment methods (hormones,
interferon), and reduce the number of operations and interventions and to provide a clinical
basis for the application of the new therapeutics model of IHHE of "propranolol + sequential
sirolimus treatment".